The effects of dexmedetomidine and ketamine infusions on the inflammatory response in liver resection: A randomized double-blind placebo study

Medicine (Baltimore). 2025 Jul 4;104(27):e42999. doi: 10.1097/MD.0000000000042999.

Abstract

Background: This study compared the effects of ketamine and dexmedetomidine (Dex) on inflammation and pain in liver resection surgery.

Methods: Forty-five American Society of Anesthesiologists class III patients aged 18 to 65 scheduled for liver resection surgery were randomized into 3 equal groups. The ketamine group received an intravenous ketamine bolus (0.5 mg/kg) during anesthesia induction and continuous low-dose infusion at 0.25 mg/kg/hour. In the Dex group, intravenous infusion was initiated at a 1 µg/kg bolus for the first 10 minutes, and at 0.5 µg/kg/hour after intubation. The control group patients were infused crystalloid solution at 8 mL/kg/hour from induction. Venous blood was collected at postoperative hours 1 and 12 for pentraxin 3, serum amyloid A, hepcidin, and inflammatory marker analysis. Visual analogue scale (VAS) values were recorded.

Results: Pentraxin 3, serum amyloid A, and hepcidin continued to rise at 12 hours in the control group, but began declining in the Dex and ketamine infusion groups (P < .05). VAS levels and fentanyl consumption decreased in the ketamine and Dex groups compared to the control group (P < .05). The decreases in inflammatory parameters, VAS scores, and fentanyl consumption were similar between the ketamine and Dex groups (P > .05). A positive correlation was observed between inflammation levels and pain severity (P < .001). There was no difference in liver function tests between any of the groups (P < .05).

Conclusion: Ketamine and Dex infusions were both effective in reducing inflammation and pain following liver resection, with no obvious superiority of one over the other.

Trial registration: ClinicalTrials.gov NCT06219928.

Keywords: dexmedetomidine; inflammation; infusion; ketamine; liver resection; pain.

Publication types

  • Randomized Controlled Trial

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Analgesics* / administration & dosage
  • C-Reactive Protein / analysis
  • Dexmedetomidine* / administration & dosage
  • Dexmedetomidine* / therapeutic use
  • Double-Blind Method
  • Female
  • Hepatectomy* / adverse effects
  • Humans
  • Inflammation* / drug therapy
  • Infusions, Intravenous
  • Ketamine* / administration & dosage
  • Ketamine* / therapeutic use
  • Male
  • Middle Aged
  • Pain Measurement
  • Pentraxins
  • Postoperative Pain* / drug therapy
  • Postoperative Pain* / prevention & control
  • Serum Amyloid A Protein / analysis
  • Serum Amyloid P-Component / analysis
  • Young Adult

Substances

  • Ketamine
  • Dexmedetomidine
  • Serum Amyloid P-Component
  • C-Reactive Protein
  • Serum Amyloid A Protein
  • Analgesics
  • Pentraxins

Associated data

  • ClinicalTrials.gov/NCT06219928